AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1623899
Drug: Furosemide 20
RxNorm normalized name: furosemide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 20 mg IV
Trial: 20409311
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aerobic and resistance training
Trial: 15710957
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with pegylated interferon-alpha2b (1.5 microg/kg/week for 32 weeks) plus lamivudine (100 mg daily for 52 weeks)
Trial: 15710957
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy (100 mg daily for 52 weeks)
Trial: 12804927
Drug: High CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CRP group (CRP >12 mg/l)
Trial: 12804927
Drug: Low CRP
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low CRP group (CRP ≤12 mg/l)
Trial: 11029125
Drug: Tramadol drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol drops (2.5 mg kg(‐1))
Trial: 11029125
Drug: Paracetamol (acetaminophen)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (acetaminophen) suppositories (15 mg kg(‐1))
Trial: 8711649
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators or steroids
Trial: 8711649
Drug: Potential improvement
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential improvement on treatment
Trial: 1355345
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg/day for 15 days
Trial: 1355345
Drug: Astemizole 10
RxNorm normalized name: astemizole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole 10 mg/day for 15 days
Trial: 6432869
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (NG) for 48 hours
Trial: 31731467
Drug: Coffee ingestion
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee ingestion (0.09 g·kg‐1 coffee providing 3 mg·kg‐1 of caffeine)
Trial: 25583754
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg/linagliptin 5 mg
Trial: 25583754
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg/linagliptin 5 mg
Trial: 18758125
Drug: Rosuvastatin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 2.5 mg/dL
Trial: 18758125
Drug: Non-rosuvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-rosuvastatin therapy
Trial: 12621384
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg orally twice a day for 2 days
Trial: 12621384
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice 200 mL 3 times a day for 2 days
Trial: 10321418
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg conventional ondansetron tablet (OT) taken twice daily
Trial: 10321418
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg orally disintegrating ondansetron tablet (ODT) taken twice daily
Trial: 2883698
Drug: midazolam 15
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 15 mg orally followed by intravenous saline
Trial: 2883698
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo followed by intravenous diazepam 10 mg (Diazemuls)
Trial: 25186034
Drug: Placebo advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo advanced to tofacitinib 5 mg twice daily
Trial: 25186034
Drug: Placebo advanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo advanced to tofacitinib 10 mg twice daily
Trial: 23850450
Drug: AC-T without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AC-T without primary G-CSF prophylaxis
Trial: 23850450
Drug: TAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC with primary G-CSF prophylaxis
Trial: 21670542
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg b.i.d.
Trial: 21670542
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg b.i.d.
Trial: 21670542
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.0-3.0; 2.0-2.6 if age ≥ 70 years)
Trial: 19567532
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DHEA daily for 2 years (women)
Trial: 19567532
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg DHEA daily for 2 years (men)
Trial: 19567532
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg testosterone (patch) daily for 2 years (men)
Trial: 19567532
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 2 years (women and men)
Trial: 16123739
Drug: DMT (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT (low dose)
Trial: 16123739
Drug: DMT (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT (high dose)
Trial: 16123739
Drug: S-ketamine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (low dose)
Trial: 16123739
Drug: S-ketamine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (high dose)
Trial: 11313302
Drug: CDP571 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 (10 or 20 mg/kg)
Trial: 7977475
Drug: Cefuroxime axetil,
RxNorm normalized name: Cefuroxime Axetil, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil, 125 mg twice a day for 2 days
Trial: 7977475
Drug: Cefuroxime axetil,
RxNorm normalized name: Cefuroxime Axetil, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil, 125 mg twice a day for 10 days
Trial: 23341981
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow mononuclear cell transplantation (BMMCT) combined with standard medical therapy (SMT)
Trial: 20462466
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus Self-Administered Cognitive Behavior Therapy (SCBT)
Trial: 9372546
Drug: Porfiromycin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porfiromycin (50 mg/M2, 45 mg/M2, 40 mg/M2) with radiation therapy (RT)
Trial: 9372546
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C with radiation therapy (RT)
Trial: 8403155
Drug: Intrathecal meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal meperidine 1 mg.kg‐1
Trial: 8403155
Drug: 5% heavy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% heavy lidocaine 1.2 to 1.4 ml intrathecally
Trial: 3512080
Drug: mazindol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mazindol (1 mg)
Trial: 27181196
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for 3 months
Trial: 20398300
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days moxifloxacin 400 mg/d with amoxycillin 1 g twice daily and lansoprasole 30 mg twice daily
Trial: 20398300
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days moxifloxacin 400 mg/d with amoxycillin 1 g twice daily and lansoprasole 30 mg twice daily
Trial: 16143734
Drug: Alprazolam 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1.5 mg/d
Trial: 11953922
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.6 g/kg/d)
Trial: 7579027
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of reboxetine (2, 3, 4, and 5 mg)
Trial: 7579027
Drug: Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4 mg therapeutic tablet formulation)
Trial: 7579027
Drug: Reboxetine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (various doses)
Trial: 1834808
Drug: Toremifene (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (10, 20, 40, 60, 200, or 400 mg/d orally) for at least 8 weeks
Trial: 6772047
Drug: Dihydrazinophthalazine (Nepresol)
RxNorm normalized name: Dihydrazinophthalazine
DrugBank: Dihydralazine (DB12945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrazinophthalazine (Nepresol) 45 +/- 12 mg
Trial: 30337189
Drug: Weaning at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weaning at 1600 g
Trial: 28506538
Drug: Nexvax2 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexvax2 60 μg
Trial: 28506538
Drug: Nexvax2 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexvax2 90 μg
Trial: 28506538
Drug: Nexvax2 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexvax2 150 μg
Trial: 28506538
Drug: Nexvax2 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexvax2 150 μg (biopsy cohort)
Trial: 28506538
Drug: Nexvax2 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexvax2 300 μg
Trial: 28506538
Drug: Nexvax2 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexvax2 150 μg (MTD)
Trial: 26482674
Drug: HPV vaccine-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine-specific brochure, telephone recalls to parents who declined, and recalls to patients overdue for doses 2 and 3
Trial: 26482674
Drug: General adolescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General adolescent vaccine brochure (active comparison)
Trial: 24429154
Drug: Nebulised MgSO(4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised MgSO(4) (three 500 mg doses in 1 h) alongside standard therapy
Trial: 24429154
Drug: Intravenous MgSO(4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous MgSO(4) (2 g in 20 min) alongside standard therapy
Trial: 24429154
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control plus standard therapy alone
Trial: 19953707
Drug: Lanreotide 30
RxNorm normalized name: lanreotide 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 30 mg PR
Trial: 3727190
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor training program (5 weekly lessons guided by trained physiotherapists)
Trial: 30689800
Drug: Reduced ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced ticagrelor maintenance dose (60 mg b.i.d)
Trial: 30689800
Drug: Standard ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard ticagrelor maintenance dose (90 mg b.i.d)
Trial: 22545007
Drug: Monthly magazines
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly magazines and newsletters aimed at promotion of healthy eating
Trial: 20832366
Drug: fixed‐dose artesunate‐mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed‐dose artesunate‐mefloquine
Trial: 20832366
Drug: primaquine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: primaquine (0.75 mg/kg)
Trial: 2019665
Drug: Epinephrine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.2 mg/inh) followed by theophylline (130 mg) with ephedrine (24 mg)
Trial: 2019665
Drug: Metaproterenol (0.65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (0.65 mg/inh)
Trial: 2019665
Drug: Placebo inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler and tablets
Trial: 7056196
Drug: human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human milk (1.6 g/100 kcal)
Trial: 7056196
Drug: formula 1
RxNorm normalized name: Abena Man Formula 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formula 1 (2.3 g/100 kcal)
Trial: 7056196
Drug: formula 2
RxNorm normalized name: Formula 21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formula 2 (3.0 g/100 kcal)
Trial: 7056196
Drug: formula (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formula (1.6 g/100 kcal, 2.3 g/100 kcal, 3.0 g/100 kcal)
Trial: 25185149
Drug: Pulmonary rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary rehabilitation program (3 months, twice-weekly, 90-min exercise sessions, total 24 sessions)
Trial: 20137596
Drug: Intravenous flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous flurbiprofen 100 mg before surgery (Group A)
Trial: 20137596
Drug: Intravenous flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous flurbiprofen 100 mg at the end of surgery (Group C)
Trial: 16685553
Drug: 48-week strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48-week strength training, performed twice per week, consisting of three series of 10 repetitions of calf-rise at 75% of the 3-repetition maximum.
Trial: 16019074
Drug: No initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No initial treatment
Trial: 12136369
Drug: Tezosentan (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan (6.25 mg/h and 25 mg/h for 6 h) with cyclosporin (400 mg single dose)
Trial: 12136369
Drug: Tezosentan (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan (6.25 mg/h and 25 mg/h for 6 h) alone
Trial: 10597779
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ZDV-ddC, ZDV-ddI, D4T-ddI, three-drug regimen)
Trial: 10597779
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen (stavudine, lamivudine, ritonavir)
Trial: 10597779
Drug: Two-drug groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug groups
Trial: 1957876
Drug: Oral communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral communication channel
Trial: 7036281
Drug: LMF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMF plus BCG (greater than 90% of planned LMF dose)
Trial: 22562783
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of moxifloxacin 0.5%/dexamethasone 0.1% ophthalmic solution
Trial: 22562783
Drug: Moxifloxacin 0.5%
RxNorm normalized name: Moxifloxacin 0.5%, Bromfenac 0.075% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 0.5% ophthalmic solution and dexamethasone 0.1% (concomitant group)
Trial: 14641923
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg, t.d.s.)
Trial: 10965102
Drug: Ondansentron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansentron 8 mg every 8 hours with dexamethasone 8 mg before cisplatin infusion and continued after 8 and 16 hours.
Trial: 10965102
Drug: Ondansentron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansentron 8 mg every 6 hours with dexamethasone 8 mg before cisplatin infusion and continued after 6, 12, and 18 hours.
Trial: 10965102
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received a total dose of 24 mg ondansentron during the acute phase of emesis.
Trial: 1795315
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mineral baths and mud packs (Group 1)
Trial: 6225751
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg bw
Trial: 6225751
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg bw
Trial: 6225751
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg bw
Trial: 25619045
Drug: Intra-articular sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular sodium hyaluronate (1%; 2,2-2,7 MDa), administered once weekly for 3 weeks (3 injections)
Trial: 25619045
Drug: Symptomatic slow-acting
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic slow-acting drugs for osteoarthritis (SYSADOA)
Trial: 22349603
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) at 6 weeks after surgery
Trial: 17668086
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide bleaching agents (3M Zaris, 3M Espe; Nite White Excel, Discus Dental)
Trial: 11493236
Drug: Alfentanil-morphine mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil-morphine mixture (0.75 : 10 mg)
Trial: 9808867
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A levels > 3 mg/kg/day
Trial: 11262334
Drug: HMG-CoA-reductase inhibitors
RxNorm normalized name: HMG CoA reductase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG-CoA-reductase inhibitors
Trial: 9808867
Drug: Strategies for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies for blocking T-cell costimulation and expression of adhesion molecules, cytokines and antiendothelial antibodies, antiproliferative drugs, methods to augment endogenous nitric oxide bioavailability, newer immunosuppressive regimens
Trial: 3181646
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (4.0 g omega-3 fatty acids)
Trial: 3181646
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (7.5 g omega-3 fatty acids)
Trial: 27056846
Drug: MAXout treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAXout treatment (18-week treatment, two 90-minute sessions per week)
Trial: 19407804
Drug: Verapamil SR-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil SR-based antihypertensive treatment
Trial: 19407804
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Verapamil and Atenolol)
Trial: 15126313
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment to eradicate H pylori infection
Trial: 9781431
Drug: Sparfloxacin 200
RxNorm normalized name: sparfloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 200 mg administered 1 hour before urethrocystoscopy
Trial: 9781431
Drug: Fleroxacin 200
RxNorm normalized name: fleroxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 200 mg administered 1 hour before urethrocystography
Trial: 9781431
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (control group) for both procedures
Trial: 3244560
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (4 mg.kg b.w.‐1)
Trial: 22930491
Drug: Mindfulness‐Based Stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness‐Based Stress Reduction (MBSR) plus treatment as usual (TAU)
Trial: 18454988
Drug: Early steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early steroid reduction (G1; n = 31)
Trial: 18454988
Drug: Regular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular steroid dosage maintenance (G2; n = 29)
Trial: 14728104
Drug: Olanzapine (7.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (7.5-20 mg/day)
Trial: 2914436
Drug: Epiquick patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epiquick patch test on the left side
Trial: 2914436
Drug: Epiquick patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epiquick patch test on the right side
Trial: 770080
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg azapropazone daily
Trial: 770080
Drug: 3.9 g
RxNorm normalized name: aspirin 3.9 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.9 g aspirin daily
Trial: 28326559
Drug: RG7652 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7652 (10, 40, 150, 300, 600, or 800 mg single dose)